Aviva
MDGL icon

Aviva’s Madrigal Pharmaceuticals MDGL Stock Holding History

Aviva’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,495
Closed -$1.23M – 934
2021
Q1 		$1.23M Buy
10,495
+355
+4% +$41.4K 0.01% 805
2020
Q4 		$1.13M Sell
10,140
-8,219
-45% -$1M 0.01% 846
2020
Q3 		$2.18M Sell
18,359
-3,871
-17% -$420K 0.01% 756
2020
Q2 		$2.52M Sell
22,230
-29,642
-57% -$2.91M 0.02% 566
2020
Q1 		$3.46M Buy
51,872
+32,721
+171% +$2.73M 0.03% 615
2019
Q4 		$1.75M Buy
+19,151
New +$1.86M 0.01% 832

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Aviva's MDGL Position: Q2 2021 in Review

Aviva sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2021, closing a stake of 10,495 shares — an estimated $1.23M sold.

Aviva first reported a position in MDGL in Q4 2019 and held it in 6 quarters. The position peaked at $3.46M in Q1 2020. 151 funds tracked by Wall St. Rank hold MDGL as of Q2 2021.

  • Aviva reported no remaining Madrigal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 10,495 Madrigal Pharmaceuticals shares in Q2 2021, an estimated $1.23M.
  • Aviva first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Aviva's Madrigal Pharmaceuticals position peaked at $3.46M in Q1 2020.
  • 151 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.